SCHEMBL873426

SCHEMBL873426

Cc1ccc(-c2cc3ccccn3c2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
NPC1 O15118 6/20 0.62
RAB9A P51151 6/20 0.62
SMN1; SMN2 Q16637 5/20 0.62
MAPT P10636 4/20 0.62
KDM4E B2RXH2 4/20 0.62
POLB P06746 2/20 0.62
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
HRH3 Q9Y5N1 6/20 0.47
ALDH1A3 P47895 2/20 0.42
SLC2A1 P11166 1/20 0.42
ALOX15 P16050 1/20 0.40
GAA P10253 3/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
HPGD P15428 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942764 0.84 ALDH1A1 (0.65) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3884828 0.82 SMN1; SMN2 (0.58) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1853028 0.81 ALDH1A1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1849445 0.81 RAB9A (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL28658650 0.81 NPC1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29089761 0.81 ALDH1A1 (0.62) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1847594 0.81 RAB9A (0.61) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL7169890 0.81 ALDH1A1 (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL321553 0.78 ALOX15 (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3885389 0.78 MAPT (0.57) ALDH1A1NPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796800-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2017-10-24 US claimed
US-20160108153-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2016-04-21 US claimed
US-9249244-B2 Process for producing polydienes BRIDGESTONE CORPORATION (JP) 2016-02-02 US claimed
EP-2619233-A1 PROCESS FOR PRODUCING POLYDIENES Bridgestone Corporation (JP) 2013-07-31 EP claimed
WO-2012040026-A1 PROCESS FOR PRODUCING POLYDIENES BRIDGESTONE CORPORATION (JP) 2012-03-29 WO claimed
CN-115537853-B Direct electrochemical synthesis method of triarylamine compound 浙江工业大学 2025-01-10 CN disclosed
CN-117758282-A Electrocatalytic preparation method of (indolizine-3-yl) -ethanedione derivative 上海陶术生物科技有限公司 2024-03-26 CN disclosed
CN-116272256-A Method and device for collecting tobacco fragrance in redried tobacco tail gas 云南烟叶复烤有限责任公司 2023-06-23 CN disclosed
CN-115537853-A Direct electrochemical synthesis method of triarylamine compound 浙江工业大学 2022-12-30 CN disclosed
CN-113582989-B Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2022-07-08 CN disclosed
CN-113582989-A Preparation method of cyanized or thiocyanized indolizine and derivatives thereof 广东药科大学 2021-11-02 CN disclosed
CN-111138432-B Method for preparing pyrrole [2,1,5-cd ] indolizine ring derivative through metal-free photocatalysis 广东药科大学 2021-03-19 CN disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed
EP-1888063-A1 ANTIFUNGAL AGENTS F2G Ltd. (GB) 2008-02-20 EP disclosed
WO-2006123145-A1 ANTIFUNGAL AGENTS F2G LTD (GB) 2006-11-23 WO disclosed
EP-0480204-B1 Imidazole derivatives, potent and selective antagonists of angiotensin II receptor FUJISAWA PHARMACEUTICAL CO (JP) 1996-03-20 EP disclosed
US-5215994-A Treating or preventing hypertension or heart failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-06-01 US disclosed
US-5210092-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-05-11 US disclosed
EP-0480204-A1 Imidazole derivatives, potent and selective antagonists of angiotensin II receptor FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 ALDH1A1 510/4885NPC1 1899/4885RAB9A 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.